Skip to main content

Sigma-Aldrich Q4 Revs Climb 13 Percent on ‘Robust’ Sales Across the Board

NEW YORK (GenomeWeb News) —Sigma-Aldrich today said fourth-quarter revenue rose 13 percent as R&D spending increased 9 percent and net income widened 25 percent.
 
Total receipts for the three months ended Dec. 31, 2006, rose to $464.5 million from $410.5 million year over year.
 
The jump in receipts was fueled by “robust” sales in all of the company’s major units, CEO Jai Nagarkatti said, adding that the better-than-predicted growth gives the company “confidence that our strategic initiatives are gaining momentum.”
 
Revenue from Sigma’s Research Essentials division increased to $88 million from 81.3 million; Research Specialties receipts jumped to $172.6 million from $152.6 million; and Research Biotech revenue increased to $70.6 million from $64.8 million.
 
R&D spending increased to $13.3 million from $12.2 million year over year.
 
The company said profit increased to $71.6 million $57.3 million in the year-ago period.
 
Sigma-Aldrich said it had around $173.8 million in cash and equivalents as of Dec. 31, 2006.
 
The company said it expects 2007 revenues to increase roughly 7 percent year over year. Broken down, growth in Research Biotech may slip somewhat from the company’s earlier predictions from around 10 percent to between 7 and 9 percent.
 
Sigma said organic growth in its other units should meet or exceed the goals of 4 percent for Research Essentials, 6 percent for Research Specialties, and 10 percent for its SAFC segment.
 
The company expects “modest” growth from its recent acquisitions, with Epichem expected to make the largest contribution by adding 2 percent to revenues. 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.